More
Topics
Acne
Cosmetic
Eczema
Infections
Pediatric
Practice Management
Psoriasis
Residents
Rosacea
Skin Cancer
Skin of Color
Show Filters plus Created with Sketch.
Refine By Content Type plus Created with Sketch.
Refine By Year plus Created with Sketch.
Sort By:
Relevance
Date
Despite high costs, evidence suggests that biologics are cost-effective options for moderate to severe psoriasis because of their efficacy.
Jerry Bagel, MD, FAAD; Ted Lain, MD, MBA; and Lawrence J. Green, MD
The psoriasis treatment landscape has changed dramatically during this editor’s tenure.
Jerry Bagel, MD, FAAD
The newest IL-23 blocker for psoriasis may prove to be a blockbuster, according to analysts.
Get familiar with the IL-23 monoclonal antibodies.
Experts share their psoriasis, acne, and AD wish lists for 2019.
Jerry Bagel, MD, FAAD; Peter A. Lio, MD; and Joshua Zeichner, MD
Weighing the data on Cimzia during pregnancy and lactation.
Are TNF inhibitors still the gold standard for PsA?
Largely due to adherence issues, topical treatments don't work for many scalp psoriasis patients.
Take a walk through the pathogenesis of psoriasis to understand how new and emerging therapies may offer benefit.
Clinical thought leaders share what they hope for to improve treatment in the future.
With Jerry Bagel, MD; Seemal R. Desai, MD, FAAD; Adam Friedman, MD, FAAD; and Gary Goldenberg, MD
Director, Psoriasis Treatment Center of Central New Jersey
Jerry Bagel, MD, FAAD shares his thoughts on why phototherapy should be part of the psoriasis treatment armamentarium. He discusses the benefits of...
Jerry Bagel MD
DermTube Journal Club
Psoriasis specialist Jerry Bagel, MD speaks with host Joshua Zeichner, MD about new Treatment Guidelines, their impact on clinical decision making,...
Jerry Bagel MD, Joshua Zeichner, MD, FAAD
VIEW MORE